China Firm Gets First U.S. Approval To Begin TCM Clinical Trials
This article was originally published in PharmAsia News
A traditional Chinese medicine has received U.S. clearance to begin clinical trials on the way to possible FDA approval as a marketable drug in the country. The Shanghai University of Traditional Chinese Medicine developed the medicine capsule it calls Fuzheng Huayu. The medicine relies on a compound of six herbs to treat hepatitis C patients who have developed fibrosis of the liver. If approved by U.S. FDA, it would be the first TCM from China to receive clearance. (Click here for more
You may also be interested in...
US President Joe Biden has invoked the Defense Production Act to ramp up COVID-19 tests and personal protective equipment. See what AdvaMed’s CEO Scott Whitaker wrote in a letter to Biden where he asked that the device industry be included in the administration’s decision-making process.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.